New Parkinson's drug enters first human safety trial
Symptom relief
Recruiting now
This early-stage study tests a single dose of SER-252 in 40 people with Parkinson's disease who experience motor fluctuations (times when symptoms worsen). The main goal is to check safety and how the drug moves through the body. Participants receive either the drug or a placebo,…
Phase: PHASE1 • Sponsor: Serina Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC